Latest progress on the launch of margetuximab in China

Margetuximab (margetuximab-cmkb)As a newFc engineered monoclonal antibody, it has attracted widespread attention in the field of HER2-positive tumor treatment in recent years. HER2 protein is mainly highly expressed on the surface of solid tumor cells such as breast cancer and gastroesophageal cancer, and is an important driver of tumor proliferation and metastasis. Margetuximab targets HER2 and blocks its signal transduction. At the same time, it significantly enhances the killing activity of immune effector cells with the help of the optimized Fc region, which reflects the current cutting-edge technology of antibody drug development. This drug has been approved for marketing in China in 2023, marking a new breakthrough in HER2 targeted therapy in China.

Compared with the traditional HER2 antibody trastuzumab, the most significant innovation of margetuximab is that it has undergone MacroGenics' unique Fc region optimization technology. This technology enhances the binding affinity of the antibody to the activating Fc receptor FCGR3A (CD16A) on immune cells, while reducing the binding to the inhibitory Fc receptor FCGR2B (CD32B). Preclinical studies have shown that this design significantly improves the antibody-dependent cytotoxicity (ADCC) effect and activates the killing function of natural killer cells (NK cells) and other effector immune cells, thereby demonstrating stronger tumor cell elimination capabilities in vitro. Although in vitro data show significant advantages, their clinical significance needs to be verified through large-scale clinical trials.

This was initially verified inSOPHIA’s global phase III clinical trial. The study compared margetuximab with trastuzumab in patients with advanced HER2-positive breast cancer who had received prior anti-HER2 therapy. The results showed that patients treated with margetuximab had a significant improvement in progression-free survival (PFS), indicating the drug's advantage in delaying disease progression. In addition, the SOPHIA trial also evaluated safety and tolerability. The overall adverse reactions were similar to trastuzumab, and no new serious safety risks were found, indicating that its safety is within the acceptable range.

In China, the approval of margituximab meets the new clinical demand forHER2-targeted therapy, especially for patients who have previously received trastuzumab treatment but had limited efficacy. As a first-line or later-line treatment option, the introduction of margetuximab has enriched treatment options and brought more possibilities for survival benefits to patients. In addition, with the continuous advancement of domestic tumor immunotherapy technology, margetuximab is expected to be used in combination with other immune checkpoint inhibitors or targeted drugs to explore better treatment combinations to further improve the efficacy.

Currently, many domestic cancer centers and tertiary hospitals have carried out clinical applications and related research on margetuximab, and gradually accumulated patient data to provide an empirical basis for optimizing treatment strategies in the future. After the drug was put on the market, patients' awareness and acceptance of the drug have gradually increased. In particular, patients who have experience in trastuzumab treatment but have developed drug resistance or disease progression have shown higher concern for margetuximab.

Overall, the launch of margituximab in China marksHER2-targeted therapy has entered a new stage of development. It not only inherits the advantages of traditional anti-HER2 antibodies in blocking tumor growth, but also greatly improves the immune effector mechanism through Fc region optimization, bringing better clinical efficacy potential.

Reference materials:https://www.margenza.com/